Get the Stockscreener App
1.095
2.27%
-0.005
Milestone Pharmaceuticals Inc stock is traded at $1.095, with a volume of 1.37M.
It is down -2.27% in the last 24 hours and down -9.28% over the past month.
Milestone Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of cardiovascular medicines. Its approved product CARDAMYST (etripamil) nasal spray is available in the United States and is the self-administered treatment for use by patients anywhere, anytime an attack of PSVT occurs. It operates in single segment.
See More
Previous Close:
$1.10
Open:
$1.12
24h Volume:
1.37M
Relative Volume:
0.94
Market Cap:
$135.70M
Revenue:
$1.78M
Net Income/Loss:
$-68.36M
P/E Ratio:
-1.6037
EPS:
-0.6828
Net Cash Flow:
$-51.59M
1W Performance:
-14.68%
1M Performance:
-9.28%
6M Performance:
-36.76%
1Y Performance:
-36.76%
1-Day Range:
$1.07
$1.14
1-Week Range:
$1.04
$1.29
52-Week Range:
$1.00
$3.06
Milestone Pharmaceuticals Inc Stock (MIST) Company Profile
Name
Milestone Pharmaceuticals Inc
Sector
Industry
Phone
(514) 336-0444
Address
1111 BOUL. DR.-FREDERIK-PHILIPS, STE 420, MONTREAL, QC
Compare MIST vs VRTX, REGN, ARGX, RVMD, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MIST
Milestone Pharmaceuticals Inc
|
1.09 | 136.95M | 1.78M | -68.36M | -51.59M | -0.6828 |
VRTX
Vertex Pharmaceuticals Inc
|
515.33 | 128.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
807.80 | 82.72B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
992.01 | 53.26B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
212.13 | 43.66B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
362.05 | 39.31B | 5.76B | 514.49M | 1.10B | 4.4813 |
Milestone Pharmaceuticals Inc Stock (MIST) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-10-26 | Initiated | Raymond James | Strong Buy |
| Dec-15-25 | Upgrade | TD Cowen | Hold → Buy |
| Sep-11-25 | Initiated | Wells Fargo | Overweight |
| Jun-05-25 | Resumed | H.C. Wainwright | Buy |
| Aug-22-24 | Initiated | Rodman & Renshaw | Buy |
| Jun-20-23 | Downgrade | Jefferies | Buy → Hold |
| Apr-22-22 | Upgrade | Piper Sandler | Neutral → Overweight |
| Mar-05-21 | Initiated | H.C. Wainwright | Buy |
| Jul-29-20 | Upgrade | Oppenheimer | Perform → Outperform |
| Jul-24-20 | Upgrade | Jefferies | Hold → Buy |
| Mar-25-20 | Downgrade | Jefferies | Buy → Hold |
| Mar-24-20 | Downgrade | Oppenheimer | Outperform → Perform |
| Mar-24-20 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jun-04-19 | Initiated | Oppenheimer | Outperform |
| Jun-03-19 | Initiated | Cowen | Outperform |
| Jun-03-19 | Initiated | Jefferies | Buy |
| Jun-03-19 | Initiated | Piper Jaffray | Overweight |
View All
Milestone Pharmaceuticals Inc Stock (MIST) Latest News
Milestone’s FDA Win Now Faces A Tougher Test: Sales - Finimize
What is HC Wainwright's Forecast for MIST Q3 Earnings? - MarketBeat
TD Cowen Maintains Milestone Pharmaceuticals(MIST.US) With Buy Rating, Maintains Target Price $8 - moomoo.com
Earnings To Watch: Milestone Scientific Inc (MLSS) Q2 2026 -- GF Value Sees 13% Upside - finance.yahoo.com
What is HC Wainwright's Estimate for MIST FY2028 Earnings? - MarketBeat
Wells Fargo Maintains Milestone Pharmaceuticals(MIST.US) With Buy Rating, Maintains Target Price $7 - Moomoo
Milestone Pharmaceuticals earnings missed by $0.02, revenue topped estimates - Investing.com Canada
Milestone Pharmaceuticals Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
Milestone Pharmaceuticals (NASDAQ:MIST) Releases Earnings Results, Misses Expectations By $0.01 EPS - MarketBeat
Milestone Pharmaceuticals Releases Q2 2026 Financial Results - AlphaStreet
Milestone Pharmaceuticals Q2 Earnings Call Highlights - MarketBeat
Milestone Pharmaceuticals Q2 Results: Net loss widens to $28.6M - scanx.trade
Milestone Pharmaceuticals Inc (MIST) Stock Forecast, Price Targets and Analysts Predictions - GuruFocus
Milestone Pharmaceuticals Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Earnings call transcript: Milestone posts Q2 loss as CARDAMYST launch gains traction - Investing.com
Q2 2026 Milestone Pharmaceuticals Inc Earnings Call Transcript - GuruFocus
Form 8K MILESTONE PHARMACEUTICALS INC. For: 12 August By Investing.com - Investing.com South Africa
Milestone Pharmaceuticals (MIST) Reports Q2 Loss, Lags Revenue Estimates - Yahoo Finance
Milestone Pharmaceuticals shares tumble after Q2 earnings miss - Yahoo Finance
Form 8K MILESTONE PHARMACEUTICALS INC. For: 12 August - Investing.com India
Milestone Pharmaceuticals stock tumbles 12% on Q2 earnings miss By Investing.com - Investing.com Nigeria
Milestone Pharmaceuticals reports Q2 2026: $0.6M product revenue, $28.6M net loss, $170.6M cash - TradingView
Milestone Pharmaceuticals stock tumbles 12% on Q2 earnings miss - Investing.com
Milestone Pharmaceuticals: Q2 Earnings Snapshot - marketscreener.com
Milestone Pharmaceuticals Inc. Q2 2026: Revenue $0.6M, EPS $(0.21) — 10-Q Summary - TradingView
Press Release: Milestone Pharmaceuticals Announces Second Quarter 2026 Financial Results and Provides Corporate Update - Moomoo
What To Expect From Milestone Pharmaceuticals Inc (MIST) Q2 2026 Earnings - Yahoo Finance
Milestone Pharmaceuticals Inc expected to post a loss of 19 cents a shareEarnings Preview - TradingView
Milestone Pharmaceuticals (MIST): Pavaki Capital group reports 7.3% ownership stake - Stock Titan
Milestone Pharmaceuticals (MIST) Expected to Announce Earnings on Wednesday - MarketBeat
Milestone Pharmaceuticals sets Aug. 12, 8:30 a.m. webcast - Stock Titan
Milestone Pharmaceuticals Inc. (NASDAQ:MIST) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Milestone Pharmaceuticals Inc (MIST) Valuation: PE, PB & Fair Value Analysis - TradingKey
After Plunging 20.2% in 4 Weeks, Here's Why the Trend Might Reverse for Milestone Pharmaceuticals (MIST) - Yahoo Finance
Milestone Pharmaceuticals Inc - TradingKey
Milestone Pharmaceuticals Inc (MIST) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Milestone Pharmaceuticals Inc (MIST) Cash Flow - TradingKey
Milestone Pharmaceuticals Inc (MIST) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
MIST|Milestone Pharmaceuticals Inc|Price:1.100|Chg%:+0.030 - TradingKey
TradingKey - TradingKey
MIST|Milestone Pharmaceuticals Inc|Price:1.160|Chg%:-0.040 - TradingKey
Milestone Pharmaceuticals (MIST) Declines 3.33% as Stock Tests Key Support at $1.10Median Line - dars.gov.et
Milestone Pharmaceuticals Inc. Revenue Breakdown – NASDAQ:MIST - TradingView
Milestone Pharmaceuticals Inc (MIST) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Wells Fargo Maintains Milestone Pharmaceuticals(MIST.US) With Buy Rating, Cuts Target Price to $7 - Moomoo
Milestone Pharmaceuticals (MIST) Q4 2024 earnings summary - Quartr
Vanda Pharmaceuticals Announces EMA Positive Opinion for Orphan Drug Designation of Imsidolimab for Generalized Pustular PsoriasisA Milestone Recognition of GPP as a Distinct Rare Disease in Europe - PR Newswire
Phio Pharmaceuticals Announces Patent Milestone with Multiple Notices of Allowance and Grant Decision - TMX Newsfile
Milestone Pharmaceuticals (NASDAQ:MIST) Stock Rating Upgraded by Zacks Research - MarketBeat
Price to book forward of Milestone Pharmaceuticals Inc. – NASDAQ:MIST - TradingView
Milestone Pharmaceuticals (MIST) Faces Downward Pressure Near Key SupportParabolic SAR - po-news-eg.net
Milestone Pharmaceuticals Inc Stock (MIST) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.00%
0.02%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):